230 related articles for article (PubMed ID: 15497016)
1. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.
Tobu M; Iqbal O; Hoppensteadt D; Neville B; Messmore HL; Fareed J
Clin Appl Thromb Hemost; 2004 Oct; 10(4):301-9. PubMed ID: 15497016
[TBL] [Abstract][Full Text] [Related]
2. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Tobu M; Iqbal O; Hoppensteadt DA; Shultz C; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2002 Oct; 8(4):325-36. PubMed ID: 12516682
[TBL] [Abstract][Full Text] [Related]
3. Influence of different anticoagulant agents on fibrinopeptide a generation.
Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
[TBL] [Abstract][Full Text] [Related]
4. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
Siegmund HU; Burghaus R; Kubitza D; Coboeken K
Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
[TBL] [Abstract][Full Text] [Related]
5. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
Kubitza D; Becka M; Mück W; Krätzschmar J
Br J Clin Pharmacol; 2014 Aug; 78(2):353-63. PubMed ID: 24528331
[TBL] [Abstract][Full Text] [Related]
7. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
[TBL] [Abstract][Full Text] [Related]
8. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
[TBL] [Abstract][Full Text] [Related]
9. Mathematical derivative applied to international normalised ratio and analytical variations in oral anticoagulant therapy control.
Introcaso G; Cuboni A; Ratto A; Foieni F
Haemostasis; 2000; 30(6):281-9. PubMed ID: 11356996
[TBL] [Abstract][Full Text] [Related]
10. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Gerbutavicius R; Iqbal O; Messmore HL; Wehrmacher WH; Hoppensteadt DA; Gerbutaviciene R; Griniute R; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):317-23. PubMed ID: 14653441
[TBL] [Abstract][Full Text] [Related]
12. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
13. Direct oral anticoagulants--interference with laboratory tests and mechanism of action.
Tsakiris DA
Semin Hematol; 2014 Apr; 51(2):98-101. PubMed ID: 24861793
[TBL] [Abstract][Full Text] [Related]
14. Standardization of coagulation tests.
Opartkiattikul N
Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
[TBL] [Abstract][Full Text] [Related]
15. Management of thrombotic and cardiovascular disorders in the new millenium.
Fareed J; Hoppensteadt DA; Bick RL
Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
[TBL] [Abstract][Full Text] [Related]
16. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
18. [Accuracy and reliability of international normalized ratio (INR) in monitoring of warfarin--comparison in the sensitivity to extrinsic coagulation factors between PT (INR) and TT (INR)].
Sakayori T; Naito S; Yoshida M; Kumano O; Kato N; Okuda M; Ieko M
Rinsho Byori; 2010 Aug; 58(8):779-85. PubMed ID: 20860170
[TBL] [Abstract][Full Text] [Related]
19. The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban.
Kim B; Jang S; Lee YJ; Park N; Cho YU; Park CJ
Br J Biomed Sci; 2019 Jul; 76(3):122-128. PubMed ID: 30967043
[No Abstract] [Full Text] [Related]
20. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio.
Johnston M; Harrison L; Moffat K; Willan A; Hirsh J
J Lab Clin Med; 1996 Aug; 128(2):214-7. PubMed ID: 8765218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
